How will the results of NRG GU006 and the use of the PAM50 genomic classifier impact treatment for recurrent prostate cancer?
Community PollStarted
Will NRG GU006 results impact your practice in the next year?
283 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on
Top line results:
The prostate cancer-adapted PAM50 gene expression biomarker was validated in the NRG GU006 randomized trial to predict the differential benefit of hormone therapy, specifically apalutamide monotherapy, for patients with recurrent prostate cancer after radical prostatectomy being tr...
Join for free or sign in to see the full answer